Teachers Retirement System of The State of Kentucky Increases Stake in TransMedics Group, Inc. $TMDX

Teachers Retirement System of The State of Kentucky increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 97.0% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,779 shares of the company’s stock after purchasing an additional 8,260 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in TransMedics Group were worth $1,668,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of TMDX. Royal Bank of Canada lifted its stake in shares of TransMedics Group by 47.9% during the first quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after acquiring an additional 868 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. lifted its position in TransMedics Group by 13.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after acquiring an additional 938 shares during the period. Finally, M&T Bank Corp acquired a new stake in TransMedics Group during the 2nd quarter worth about $209,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $75.38 on Thursday. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The firm has a market cap of $2.61 billion, a price-to-earnings ratio of 17.13 and a beta of 1.89. The firm’s fifty day moving average is $70.66 and its two-hundred day moving average is $105.14.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. During the same quarter in the previous year, the business posted $0.70 EPS. The business’s quarterly revenue was up 21.2% on a year-over-year basis. Research analysts expect that TransMedics Group, Inc. will post 1.92 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TMDX. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a report on Tuesday, June 9th. Wall Street Zen downgraded TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Zacks Research lowered TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Needham & Company LLC cut their price target on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, TD Cowen reiterated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a report on Wednesday, July 1st. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and a consensus target price of $134.50.

Insiders Place Their Bets

In related news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total transaction of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares in the company, valued at approximately $1,249,148.52. This trade represents a 36.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 6.90% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.